Get started
Author

Хотко Алкес Асланчериевич

Observed names: A A KHOTKO, A. A. Hotko, A. A. Khotko, A.A. Khotko Khotko, AA Khotko, Alkes A. Hotko, Alkes A. Khotko, Alkes Khotko, Khotko A.A., А А Хотко, А. А. Хотко, А.А. Хотко, Хотко А. А.
ORCID: 0000-0002-8688-4876
Observed ORCID: 0000-0002-8688-4876
OpenAlex ID: A5007811511
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials
2023 · Michael Sticherling, Arjen F. Nikkels, et al. · American Journal of Clinical Dermatology · 13
PDF
Inverse psoriasis and psoriasis of ‘difficult’ localizations: Effectiveness of netakimab
2022 · L. S. Kruglova, N. S. Rudneva, et al. · Medical alphabet · 10
Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis in the Russian Federation
2022 · Liudmila Odnopozova, Anton Edin, et al. · Dermatology and Therapy · 8
PDF
Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial
2022 · Alexey V. Samtsov, Andrey L. Bakulev, et al. · PLoS ONE · 8
PDF
Effectiveness of netakimab in real clinical practice in patients with severe forms of psoriasis
2020 · A. A. Hotko, L. S. Kruglova, et al. · Medical alphabet · 7
PDF
Content of CD4+T cell subpopulations in predicting the efficacy of biological therapy for psoriasis in children
2023 · D. G. Kuptsova, T. V. Radigina, et al. · Medical Immunology (Russia) · 6
PDF
Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
2018 · Т. V. Korotaeva, A. V. Samtsov, et al. · Modern Rheumatology Journal · 5
PDF
Diseases of cardiovascular system in patients with severe and moderatesevere forms of psoriasis
2021 · A. A. Hotko, M. Yu. Pomazanova, et al. · Medical alphabet · 4
Profiles of patients with psoriasis for appointment gene-engineering biological therapy — clinical justification
2020 · Alexander S. Zhukov, Alkes A. Khotko, et al. · Vestnik dermatologii i venerologii · 4
PDF
Role of MRSA strains in the pathogenesis of severe atopic dermatitis in childhood. The ways of remission achievement
2012 · N N MURASHKIN, M I GLUZMIN, et al. · Vestnik dermatologii i venerologii · 4
PDF
Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-blind trial
2026 · Pascal Joly, Dedee F Murrell, et al. · British Journal of Dermatology · 3
Efficacy and safety of netakimab therapy in patients with moderate to severe psoriasis in real clinical practice
2023 · Andrey L. Bakulev, Olga A. Pritulo, et al. · Vestnik dermatologii i venerologii · 3
PDF
Issues of switching therapy when effect of biological genetically engineered drugs escapes
2020 · L. S. Kruglova, A. A. Hotko, et al. · Medical alphabet · 3
Psoriasis and psychiatric comorbidity
2019 · L.S. Kruglova Kruglova, A.V. Pushkina Pushkina, et al. · Фарматека · 3
Resource consumption and patient employability during systemic therapy and biological therapy
2021 · L. S. Kruglova, A. A. Hotko · Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice · 2
PDF
Choice of first-line genetically engineered biological drugs for moderate and severe psoriasis in patients with comorbid pathology
2020 · L. S. Kruglova, A. A. Hotko · Medical alphabet · 2
Targeted therapy of psoriasis: inhibition of the IL-23 signaling pathway — evidence from clinical studies and real practice
2020 · Alkes A. Hotko, Marina Yu. Pomazanova, et al. · Vestnik dermatologii i venerologii · 2
PDF
Analysis of duration of remission of psoriasis after discontinuation of targeted therapy: Search for predictors of early relapse of disease
2023 · A. A. Khotko, N. N. Murashkin · Medical alphabet · 1
PDF
Assessment of CD4+ cells subpopulations with the expressing CD39 and CD73 ectonucleotidases in children with psoriasis
2022 · D. G. Kuptsova, T. V. Radigina, et al. · Medical Immunology (Russia) · 1
PDF
Pilot study of tolerability and safety of combination product containing terbinafne hydrochloride and econazole nitrate
2022 · L. S. Kruglova, A. V. Tamrazova, et al. · Medical alphabet · 1
Activity of nuclear factor κB in lymphocyte populations of children with psoriasis
2022 · DG Kuptsova, SV Petrichuk, et al. · Bulletin of Russian State Medical University · 1
PDF
Reproductive health issues in patients with psoriasis (literature review)
2019 · L. S. Kruglova, A. A. Osina, et al. · Medical alphabet · 1
Scalp Psoriasis - Topical Issues of Diagnosis and Therapy
2018 · L.S. Kruglova Kruglova, S.N. Turbovskaya Turbovskaya, et al. · Фарматека · 1
Efficacy and Safety of Netakimab in Children and Adolescents with Moderate-to-Severe Plaque Psoriasis: Results of the Core Treatment Period (12 Weeks) of the Randomized Placebo-Controlled Phase III Clinical Trial BCD-085-16/PLANETA-KIDS
2026 · Nikolay N. Murashkin, Andrey L. Bakulev, et al. · Вопросы современной педиатрии
PDF
Russian interdisciplinary consensus on the definitions of “difficult-to-manage” and “difficult-to-treat” psoriatic arthritis/psoriasis and the management of these patients
2026 · A. M Lila, T. V. Korotaeva, et al. · Modern Rheumatology Journal
PDF
Works count: 52
Citation count: 93
H-index: 6
I10-index: 2
Year
Topic
Type